Cosmo Pharmaceuticals N.V. News Releases

Cosmo Presents Agenda for AGM 2026

Thu, 12 Mar 2026 01:58:00 -0400

Dublin, Ireland--(Newsfile Corp. - March 12, 2026) - Cosmo Pharmaceuticals N.V. (“Cosmo”) is pleased to announce the convening of its upcoming Ordinary Annual General Meeting of Shareholders (AGM) to be held on 10 April 2026 in Amsterdam. The agenda includes, among others, the following discussion and voting items: Report of the Board of Directors on the business year 2025 and the ESG achievements Appropriation of the Full-Year 2025 results ...

Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework

Mon, 09 Mar 2026 02:00:00 -0400

Ad hoc announcement pursuant to Art. 53 LR Full Year 2025 revenue of €104.2 million, in line with guidance, with 85% recurring revenues Recurring revenues of €88.1 million, +15% year-over-year, reflecting structural business transformation EBITDA of €9.5 million, exceeding the upper end of guidance Cash, equivalents and investments of €128.3 million as of December 31, 2025; no financial debt Proposed...

Cosmo Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus

Thu, 05 Mar 2026 01:00:00 -0500

Dublin, Ireland--(Newsfile Corp. - March 5, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an artificial intelligence (AI)-based computer-aided detection (CADe) system for the identification of early neoplasia in Barrett’s esophagus. The collaboration represents an important step in expanding the clinical...

Cosmo to Participate in Upcoming Investor Conferences

Wed, 18 Feb 2026 01:01:00 -0500

Dublin, Ireland--(Newsfile Corp. - February 18, 2026) - Cosmo Pharmaceuticals N.V. (“Cosmo”) is pleased to announce its participation in the following upcoming investor conferences: UBS European Healthcare Conference 2026 London, United Kingdom 4 March 2026 Svetlana Sigalova, Chief Financial Officer, will participate in one-on-one meetings with investors. Jefferies Biotech Summit 2026 Miami, United States 11...

Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares

Tue, 03 Feb 2026 01:10:00 -0500

Dublin, Ireland--(Newsfile Corp. - February 3, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the successful completion of a private placement of 937,086 treasury shares. The shares were placed with Capital Group’s SMALLCAP World Fund. The placement is equivalent to approximately 5.3% of Cosmo’s outstanding shares, subject to regulatory disclosure. The placement was executed using existing treasury shares and therefore does not...

Invitation to Cosmo's Full Year 2025 Financial Results Webcast on 9 March 2026

Wed, 28 Jan 2026 01:24:00 -0500

Dublin, Ireland--(Newsfile Corp. - January 28, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Full-Year 2025 results on Monday, 9 March 2026 at 7:00 am CET. Live conference call and audio webcast presentation: Cosmo invites investors, financial analysts and business/life sciences journalists to a live webcast presentation which will follow on the same day at 10:00 am CET. ...

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Mon, 12 Jan 2026 01:02:00 -0500

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in Cosmo’s Vision 2030, strengthening the Company’s foundations for scalable, innovation-driven growth across AI-enabled MedTech and pharma. Financial Highlights: High quality growth: €104 million revenue at guidance midpoint (€102 to €107 million) with recurring revenues representing the majority of sales and accelerating year over year ...

Cosmo Announces Breakthrough Phase III Topline Results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in Male Hair Loss, Showing up to 539% Relative Improvement in Target-Area Hair Count vs Placebo; US and EU Submissions are Underway

Wed, 03 Dec 2025 01:12:00 -0500

Ad hoc announcement pursuant to Art. 53 LR 1,465 patients were randomized into the two identical-in-design clinical studies Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805) Both studies reached statistically significant endpoints in TAHC (Target-Area Hair Count), with one reaching 539% relative improvement to placebo and the second study reaching 168% relative improvement to placebo Positive safety profile demonstrated across both studies ...

Winlevi(R) Receives Regulatory Approval in Brazil - Expanding Global Access to a Breakthrough Acne Treatment

Fri, 14 Nov 2025 01:10:00 -0500

Dublin, Ireland--(Newsfile Corp. - November 14, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and dermatology innovations, today announced that the Brazilian Health Regulatory Agency (ANVISA) has approved Winlevi® (clascoterone) cream 1% for the treatment of acne vulgaris in patients aged twelve years and older. This milestone marks another key step in Cosmo’s mission to build health confidence worldwide, expanding access to its...

Cosmo's ESG Rating Upgraded by S&P Global; Strengthens Supplier Sustainability Oversight Engagement, and Italian Manufacturing Plant Awarded EcoVadis Bronze Medal

Tue, 11 Nov 2025 01:01:00 -0500

Dublin, Ireland--(Newsfile Corp. - November 11, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced two major milestones in its sustainability journey, underscoring its commitment to transparency, responsible operations, and ESG leadership. Cosmo’s 2025 S&P Global Corporate Sustainability Assessment has been upgraded to the 67th percentile, a significant improvement from last year’s 55th...